We are live on ! Find out more
CYAD

Celyad Oncology SA American Depositary Shares
CYAD

Delisted

CYAD was delisted on the 18th of May, 2023.

Back to rankings

8 hedge funds and large institutions have $8.19M invested in Celyad Oncology SA American Depositary Shares in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

44% less capital invested

Capital invested by funds: $14.7M → $8.19M (-$6.46M)

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
+$340K
2
Deutsche Bank
Deutsche Bank
Germany
+$55.3K
3
Morgan Stanley
Morgan Stanley
New York
+$47.4K
4
Wells Fargo
Wells Fargo
California
+$3.13K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$554K
2
UBS Group
UBS Group
Switzerland
-$6.9K
3
TRCT
Tower Research Capital (TRC)
New York
-$744
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
1
Victory Capital Management
Texas
$7.92M +$340K +17,850 +3%
Morgan Stanley
2
Morgan Stanley
New York
$143K +$47.4K +2,488 +25%
Wells Fargo
3
Wells Fargo
California
$89K +$3.13K +164 +2%
Deutsche Bank
4
Deutsche Bank
Germany
$33K +$55.3K +2,900 New
UBS Group
5
UBS Group
Switzerland
$6K -$6.9K -362 -42%
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$1K – – –
Zurich Cantonal Bank
7
Zurich Cantonal Bank
Switzerland
$1K – – –
Millennium Management
8
Millennium Management
New York
– -$554K -27,178 Closed
TRCT
9
Tower Research Capital (TRC)
New York
– -$744 -39 -98%

CYAD Hedge Fund Activity: Q2 2019 in Review

8 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q2 2019, worth a combined $8.19M — down 44% from $14.7M a quarter earlier.

Fund positioning in CYAD was balanced in Q2 2019: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 2 trimmed.

The largest buyer was Victory Capital Management, adding an estimated $340K. The largest seller was Millennium Management, exiting entirely with an estimated $554K sold.

  • 8 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $8.19M of Celyad Oncology SA American Depositary Shares stock for Q2 2019, down 44% quarter-over-quarter.
  • 1 fund opened new Celyad Oncology SA American Depositary Shares positions in Q2 2019 and 1 closed out, a net change of 0 holders.
  • The largest Celyad Oncology SA American Depositary Shares buyer in Q2 2019 was Victory Capital Management, an estimated $340K added.
  • The largest Celyad Oncology SA American Depositary Shares seller in Q2 2019 was Millennium Management, an estimated $554K sold.

Based on aggregated 13F filings for Q2 2019.